Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.

@article{Hardy2010TwoyearSA,
  title={Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.},
  author={William David Hardy and Roy M. Gulick and Howard B Mayer and Gerd F{\"a}tkenheuer and Mark Nelson and Jayvant R. Heera and Natasa Rajicic and James Goodrich},
  journal={Journal of acquired immune deficiency syndromes},
  year={2010},
  volume={55 5},
  pages={558-64}
}
BACKGROUND Maraviroc, the first approved CCR5 antagonist, demonstrated 48-week safety and virologic efficacy in CCR5-tropic HIV-infected, treatment-experienced patients; however, critical longer-term safety and durability of responses are unknown. METHODS Two-year follow-up of 2 prospective, randomized, blinded studies of maraviroc once daily or twice daily, or placebo in treatment-experienced patients with R5-tropic HIV-1 receiving an optimized background regimen. Unblinding occurred after… CONTINUE READING